• metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
• mNSCLC - L1 - all population 5
• mNSCLC - L1 - EGFR mutant
• mNSCLC - L1 - PDL1 negative 1
• mNSCLC - L1 - PDL1 positive 14
• mNSCLC - L1 - TMB>10Mb 1
• non squamous cell - mNSCLC - L1
• non squamous - mNSCLC - L1 - all population 3
• non squamous - mNSCLC - L1 - PDL1 positive
• non squamous - mNSCLC - L1 - Wild Type (WT) 6
• squamous cell - mNSCLC - L1
• squamous - mNSCLC - L1 - all population 4
• squamous - mNSCLC - L1 - PDL1 positive
• squamous - mNSCLC - L1 - Wild Type (WT)

 

• gene alteration target therapy
• EGFR gene alteration
• osimertinib
• HER inhibitor
• EGFR inhibitor
• erlotinib based treatment
• erlotinib alone
• erlotinib plus cisplatin and gemcitabine
• erlotinib plus SoC
• gefitinib based treatment
• gefitinib alone
• gefitinib plus BSC
• gefitinib plus SoC
• SoC followed by gefitinib
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• sintilimab based treatment
• sintillimab plus SoC
• sugemalimab based treatment
• sugemalimab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• VEGF(R) inhibitor
• sorafenib
• sorafenib and erlotinib

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs nucleoside analogues (pyrimidine/purine)
• vs gemcitabine
• vs taxanes
• vs docetaxel
• vs vinca alkaloids
• vs vinorelbine
• vs vinorelbine and platin
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs HER inhibitor
• vs EGFR inhibitor
• vs non active control
• vs no additional treatment
• vs placebo
• vs placebo plus BSC
• vs VEGF(R) inhibitor
• vs sorafenib
• vs sorafenib and gemcitabine

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)